A D.C. university and Maryland biotech are teaming up to advance medical devices for cancer therapies — and Covid-19 — to the tune of $3.2 million.

George Washington University and Takoma Park life sciences and biomedical device company US Medical Innovations LLC have entered a corporate research agreement to develop what are called adaptive cold plasma devices. The partners are now studying that technology in gastrointestinal cancer “where the surgery is done and tumor is removed, and then residual cells or surgical margins are treated with the plasma to remove small lesions,” said Michael Keidar, a professor of engineering at GWU and mechanical engineer by training.

Read the full article at: www.bizjournals.com